newsfilter
← Latest News
GlobeNewswire·

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD